Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13905628 | 0.89 | CTSL (0.61) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL742227 | 0.87 | CTSL (0.62) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL742226 | 0.87 | CTSL (0.62) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL14282774 | 0.87 | CTSL (0.59) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL1519856 | 0.87 | CTSL (0.62) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL5757441 | 0.85 | ATM (0.53) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL5755877 | 0.84 | ATM (0.70) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL8330079 | 0.84 | ATM (0.70) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL5757675 | 0.84 | ATM (0.47) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL21799327 | 0.84 | CTSL (0.64) | CTSLATMCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | disclosed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SIGMAR1, TAAR1, OPRL1 | CTSL 4664/4885ATM 3190/4885CTSS 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.